Subcutaneous injection of mRNA vaccines against severe acute respiratory syndrome coronavirus 2: an option for severe bleeding disorders or anticoagulated patients?

Blood Coagul Fibrinolysis. 2021 Sep 1;32(6):423-424. doi: 10.1097/MBC.0000000000001048.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Neutralizing / biosynthesis
  • Antibodies, Viral / biosynthesis
  • Anticoagulants / adverse effects*
  • Autoexperimentation
  • BNT162 Vaccine
  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / administration & dosage*
  • COVID-19 Vaccines / adverse effects
  • Chills / etiology
  • Contraindications, Procedure
  • Fatigue / etiology
  • Hemorrhage / chemically induced
  • Hemorrhage / etiology
  • Hemorrhage / prevention & control*
  • Hemorrhagic Disorders / complications*
  • Humans
  • Injections, Intramuscular / adverse effects
  • Injections, Subcutaneous
  • Male
  • Middle Aged
  • Punctures / adverse effects
  • Rivaroxaban / adverse effects
  • SARS-CoV-2 / immunology*

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Anticoagulants
  • COVID-19 Vaccines
  • Rivaroxaban
  • BNT162 Vaccine